Product Program year 2025 Source: CMS Open Payments

Menquadfi

Biological Vaccines

NDC 49281-590-05

Open in the dashboard

General payments

$843,764

38,064 payments

Research payments

$51,860

15 payments

Through program year 2025, $843,764 in general payments and $51,860 in research payments were reported against Menquadfi (Vaccines).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Amount Payments
2025 General $73,134 3,181
2024 General $112,239 4,763
2023 General $259,749 10,922
2022 General $244,365 10,578
2021 General $143,164 8,186
2020 General $11,113 434
2020 Research $51,860 15

Breakdown

Who paid General payments · program years 2020–2025
  1. Sanofi Pasteur Inc. $843,764 38,064 payments
Top recipients General payments · program year 2025
  1. Janet Chou Pediatrics · Long Beach, CA $314 <1% · 1 payment
  2. Ejike Onyeador Pediatrics · Long Beach, CA $167 <1% · 2 payments
  3. Michael Vicioso Nurse Practitioner, Pediatrics · Long Beach, CA $150 <1% · 2 payments
  4. James Martin Pediatrics · Tallahassee, FL $144 <1% · 5 payments
  5. Marcia Lanier Nurse Practitioner, Pediatrics · Tallahassee, FL $144 <1% · 5 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Pediatrics $41,466 58% · 1,409 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $7,341 10% · 276 practitioners
  3. Nurse Practitioner, Pediatrics Nurse Practitioner $5,867 8% · 224 practitioners
  4. Family Medicine $4,549 6% · 170 practitioners
  5. Physician Assistant $3,240 5% · 124 practitioners

The top 5 of 49 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $12,438 17% · 358 recipients
  2. Texas $11,382 16% · 386 recipients
  3. Georgia $6,571 9% · 230 recipients
  4. Florida $5,573 8% · 189 recipients
  5. Arizona $4,139 6% · 130 recipients

The top 5 of 45 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

5,638

Prescriptions dispensed, refills included

Drug cost

$930,265

Paid at the pharmacy, in all

Prescribers

96

With 11 or more claims of it

Medicare Part D drugs matched to MENQUADFI, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Menquadfi Mening Vac A,c,y,w135,c-Tet/Pf Same name 96 5,638 $930,265

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 96 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Armaghan Azad Emergency Medicine CA 566 $94,138 None on record
Alejandra Moscoso Family Practice TX 525 $76,926 None on record
Cedric Davis Family Practice IL 460 $72,293 None on record
Anthony Oliva Internal Medicine TX 314 $48,811 None on record
Weslin Thomas Family Practice IL 226 $35,852 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 96 with Patron
38,064 general · 15 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record